Geron Corp
GERN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000886744
In the last 90 days, Geron Corp insiders filed 2 open-market purchases and 0 sales; 261 institutions reported holding it in 13F filings for Q2 2026, worth $610.5M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:08 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 4, 2023 | Jan 10, 2022 |
| Revenue | – | – | $237.0K | $596.0K | $1.39M |
| Operating expenses | $252.5M | $250.7M | $194.2M | $139.1M | $115.4M |
| Research and development | $71.4M | $103.7M | $125.0M | $95.5M | $85.7M |
| Selling, general and administrative | $159.3M | $145.7M | $69.1M | $43.6M | $29.7M |
| Operating income | -$68.6M | -$173.7M | -$193.9M | -$138.6M | -$114.0M |
| Interest expense | – | $18.5M | $8.31M | $6.88M | $3.74M |
| Income tax | $75.0K | $449.0K | – | – | – |
| Net income | -$83.5M | -$174.6M | -$184.1M | -$141.9M | -$116.1M |
| EPS, basic | $-0.13 | $-0.27 | $-0.32 | $-0.37 | – |
| EPS, diluted | $-0.13 | $-0.27 | $-0.32 | $-0.37 | – |
| Weighted shares, basic | 666.7M | 646.0M | 570.6M | 380.8M | – |
| Weighted shares, diluted | 666.7M | 646.0M | 570.6M | 380.8M | – |
| Margins and growth | |||||
| Operating margin | – | – | -81832.9% | -23246.6% | -8183.7% |
| Net margin | – | – | -77690.7% | -23808.9% | -8335.4% |
| Revenue growth, year over year | – | – | −60.2% | −57.2% | +450.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 4, 2023 | Jan 10, 2022 |
| Cash and equivalents | $77.6M | $79.0M | $70.0M | $56.8M | $34.9M |
| Accounts receivable | $37.0M | $35.9M | – | – | – |
| Inventory | $116.6M | $38.7M | – | – | – |
| Total current assets | $520.3M | $491.0M | $341.3M | $180.2M | $187.2M |
| Property, plant and equipment | $884.0K | $1.31M | $1.18M | $793.0K | $650.0K |
| Total assets | $570.5M | $593.8M | $394.1M | $190.6M | $226.0M |
| Accounts payable | $11.3M | $8.60M | $6.16M | $10.2M | $6.69M |
| Short-term debt | – | – | $46.9M | $20.9M | – |
| Total current liabilities | $111.5M | $88.3M | $108.1M | $76.7M | $45.5M |
| Long-term debt | $119.5M | $118.5M | $35.1M | $30.2M | $49.8M |
| Total liabilities | $344.7M | $313.5M | $146.1M | $110.6M | $99.6M |
| Shareholders' equity | $225.9M | $280.3M | $247.9M | $80.0M | $126.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 25, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 4, 2023 | Jan 10, 2022 |
| Operating cash flow | -$111.0M | -$218.6M | -$167.7M | -$127.4M | -$95.6M |
| Capital expenditures | – | $680.0K | $830.0K | $431.0K | $207.0K |
| Free cash flow | – | -$219.3M | -$168.6M | -$127.8M | -$95.8M |
| Depreciation and amortization | $474.0K | $546.0K | $442.0K | $288.0K | $215.0K |
| Stock-based compensation | $26.7M | $31.2M | $18.5M | $8.00M | $8.08M |
| Investing cash flow | $107.2M | -$106.0M | -$180.3M | $62.1M | $71.9M |
| Financing cash flow | $2.27M | $334.4M | $362.0M | $87.3M | $48.6M |
| Net change in cash | -$1.44M | $9.74M | $13.9M | – | – |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 7816.9% | 1342.4% | 580.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 644.2M | +0.9% | SEC |
| Jul 31, 2026 | 642.5M | +0.7% | SEC |
| May 1, 2026 | 641.5M | +0.7% | SEC |
| Feb 20, 2026 | 640.5M | +0.6% | SEC |
| Nov 4, 2025 | 638.4M | +5.6% | SEC |
| Aug 1, 2025 | 638.0M | +5.8% | SEC |
| May 2, 2025 | 636.9M | +7.4% | SEC |
| Feb 21, 2025 | 636.9M | +16.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.